作者
James G Hakim, Jennifer Thompson, Cissy Kityo, Anne Hoppe, Andrew Kambugu, Joep J van Oosterhout, Abbas Lugemwa, Abraham Siika, Raymond Mwebaze, Aggrey Mweemba, George Abongomera, Margaret J Thomason, Philippa Easterbrook, Peter Mugyenyi, A Sarah Walker, Nicholas I Paton, E Agweng, P Awio, G Bakeinyaga, C Isabirye, U Kabuga, S Kasuswa, M Katuramu, F Kiweewa, H Kyomugisha, E Lutalo, D Mulima, H Musana, G Musitwa, V Musiime, M Ndigendawan, H Namata, J Nkalubo, P Ocitti Labejja, P Okello, P Olal, G Pimundu, P Segonga, F Ssali, Z Tamale, D Tumukunde, W Namala, R Byaruhanga, J Kayiwa, J Tukamushaba, S Abunyang, D Eram, O Denis, R Lwalanda, L Mugarura, J Namusanje, I Nankya, E Ndashimye, E Nabulime, O Senfuma, G Bihabwa, E Buluma, A Elbireer, D Kamya, M Katwere, R Kiggundu, C Komujuni, E Laker, E Lubwama, I Mambule, J Matovu, A Nakajubi, J Nakku, R Nalumenya, L Namuyimbwa, F Semitala, B Wandera, J Wanyama, H Mugerwa, E Ninsiima, T Ssenkindu, S Mwebe, L Atwine, H William, C Katemba, M Acaku, P Ssebutinde, H Kitizo, J Kukundakwe, M Naluguza, K Ssegawa, F Nsibuka, P Tuhirirwe, M Fortunate, J Acen, J Achidri, A Amone, M Chamai, J Ditai, M Kemigisa, M Kiconco, C Matama, D Mbanza, F Nambaziira, M Owor Odoi, A Rweyora, G Tumwebaze, H Kalanzi, J Katabaazi, A Kiyingi, M Mbidde, M Mugenyi, P Okong, I Senoga, M Abwola, D Baliruno, J Bwomezi, A Kasede, M Mudoola, R Namisi, F Ssennono, S Tuhirwe, G Amone, J Abach, I Aciro, B Arach, P Kidega, J Omongin, E Ocung, W Odong, A Philliam, H Alima, B Ahimbisibwe, E Atuhaire, F Atukunda, G Bekusike, A Bulegyeya, D Kahatano, S Kamukama, J Kyoshabire, A Nassali, A Mbonye, TM Naturinda, A Nshabohurira, H Ntawiha, A Rogers, M Tibyasa, S Kiirya, D Atwongyeire, A Nankya, C Draleku, D Nakiboneka, D Odoch, L Lakidi, R Ruganda
发表日期
2018/1/1
期刊
The Lancet Infectious Diseases
卷号
18
期号
1
页码范围
47-57
出版商
Elsevier
简介
Background
Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir as an alternative second-line combination. We assessed whether this treatment option offers any advantage over the standard protease inhibitor plus two nucleoside reverse-transcriptase inhibitors (NRTIs) second-line combination after 144 weeks of follow-up in typical programme settings.
Methods
We analysed the 144-week outcomes at the completion of the EARNEST trial, a randomised controlled trial done in HIV-infected adults or adolescents in 14 sites in five sub-Saharan African countries (Uganda, Zimbabwe, Malawi, Kenya, Zambia). Participants were those who were no longer responding to non-NRTI-based first-line ART, as assessed with WHO criteria, confirmed by …
学术搜索中的文章
JG Hakim, J Thompson, C Kityo, A Hoppe, A Kambugu… - The Lancet Infectious Diseases, 2018